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Abstract Pharyngitis is common in children, accounting for nearly 12 million visits annually in
the United States. Streptococcus pyogenes or group A streptococcus (GAS) is the most common
bacterial cause of pharyngitis for which antibiotics are indicated. Antibiotic treatment of
streptococcal pharyngitis virtually eliminates the presence of bacteria from the pharynx and
thus removes the risk of subsequent rheumatic fever. GAS is spread from person to person
via respiratory droplets with a short incubation period of 2w5 days. GAS pharyngitis peaks
in the late winter and early spring months when children are predominately indoors for school
and sports. Colonization is also higher in winter months, and while up to 20% of school age children are colonized with GAS in their throat during this time, colonization has not been shown
to contribute to the spread of disease. In low- and middle-income countries and other situations in which crowding is common (e.g., schools), outbreaks of pharyngitis are common.
GAS pharyngitis can occur at all ages and it is most common in school-aged children with a peak
at 7w8 years of age. Pharyngitis caused by GAS is rare in children <3 years of age and becomes
much less common in late adolescence through adulthood.
Copyright ª 2021 Chinese Medical Association. Publishing services by Elsevier B.V. on behalf of
KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Pharyngitis is common in children, accounting for nearly 12
million visits annually in the United States.1 Streptococcus
pyogenes or group A streptococcus (GAS) is the most common bacterial cause of pharyngitis for which antibiotics are
indicated. There are more than 240 known M protein types
encoded by the emm gene and conferring a specific emm
type. Specific emm types have long been associated with
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sequelae such as rheumatic fever (e.g. type 1) and acute
glomerulonephritis (e.g., type 12).2e4 Antibiotic treatment
of streptococcal pharyngitis virtually eliminates the presence of bacteria from the pharynx and thus removes the
risk of subsequent rheumatic fever.
GAS is spread from person to person via respiratory
droplets with a short incubation period of 2w5 days. GAS
pharyngitis peaks in the late winter and early spring months
when children are predominately indoors for school and
sports. Colonization is also higher in winter months, and
while up to 20% of school age children are colonized with
GAS in their throat during this time, colonization has not
been shown to contribute to the spread of disease.5e7 In
low- and middle-income countries and other situations in
which crowding is common (e.g., schools), outbreaks of
pharyngitis are common.8 GAS pharyngitis can occur at all
ages and it is most common in school-aged children with a
peak at 7w8 years of age. Pharyngitis caused by GAS is rare
in children <3 years of age and becomes much less common
in late adolescence through adulthood.9,10

Clinical presentation
The classic presentation of GAS pharyngitis includes sudden
onset of fever and sore throat with inflammation of the
tonsils noted on exam in the absence of viral respiratory
features.9 Tender anterior cervical lymphadenopathy is often
present. Palatal petechiae, strawberry tongue, red swollen
uvula, or scarlatiniform rash may also be present. However,
overlap with other clinical diagnoses exists (e.g., viral
pharyngitis and Kawasaki Disease) and none of these are
pathognomonic for GAS pharyngitis. Other clinical features
include headache, myalgias, vomiting, and abdominal pain.
Separating out children who may be colonized with GAS in
their pharynx from those with GAS pharyngitis can be difficult. It is recommended that streptococcal testing be avoided in children with clinical features of a viral infection such
as cough, rhinorrhea, congestion, hoarse voice, diarrhea,
conjunctivitis, coryza, or oral ulcers.9,11 Recent data from
Shapiro and colleagues supports this recommendation. They
found that children with viral features, especially rhinorrhea,
were less likely to have a positive streptococcal antigen test.
Additionally, the likelihood of a positive antigen test result
declined as the number of viral features increased.11
Typical clinical presentations of GAS tonsillitis are rare
in children <3 years of age. In young children, GAS infection generally has more of a subacute presentation with low
grade fever, fussiness, anorexia, congestion, mucopurulent
rhinorrhea, and anterior lymphadenopathy.12,13
Peritonsillar abscess
Peritonsillar abscess (PTA) is a collection of purulence between the tonsillar capsule and the pharyngeal constrictor
muscle. PTA presents similarly to streptococcal pharyngitis,
although additional clinical symptoms of dysphagia, odynophagia, drooling, muffled voice, and trismus may be present.
On exam, an apparent bulging tonsil may be seen causing
deviation of the uvula away from the abscess.14 Younger
children may be less likely to present with sore throat and
may have noted neck swelling and tenderness on exam.15
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Suppurative and non-suppurative sequelae
Children with a missed diagnosis of GAS tonsillitis are at
increased risk of developing suppurative complications such
as otitis media, sinusitis, and peritonsillar abscess (PTA),
and treatment has been shown to mitigate this risk in systematic reviews.16 However, the magnitude of the risk of
non-treatment appears to be small. Data from Little and
colleagues found that the number of GAS tonsillitis cases
needed to treat (NNT) to prevent one otitis media or
sinusitis complication was 193 for those prescribed antibiotics at the time of the initial visit and was 174 in those who
received a delayed antibiotic prescription.17 PTA is a less
frequent sequelae of GAS tonsillitis than otitis media and
sinusitis with an annual incidence of 9.4 per 100 000 children under 20 years of age. It is most common in adolescents with a peak age of 13 years.18 Similar to otitis media
and sinusitis, newer observational data suggests that immediate antibiotics are not better than either delayed or no
antibiotics in preventing PTA, indicating that early evidence of peritonsillar abscess may be present at the initial
clinical presentation.17,19 The risk of adverse events from
antibiotic exposure has been found to be much higher than
the risk of otitis media, sinusitis, and PTA following a
missed GAS pharyngitis. A recent Cochrane review found
that the risk of vomiting, diarrhea, or rash was higher for
children treated with antibiotics than those who were not
treated with a relative risk of 1.38 (95%CI 1.19 to 1.59) and
the NNT to cause a harmful outcome was 14.20
Acute rheumatic fever (ARF) occurs primarily in untreated
school-aged children aged 5w14 years with antecedent history of untreated tonsillitis.21 There are rare cases of ARF in
young children aged 2w3 years in high-risk populations.22
The Jones criteria for diagnosis of ARF was revised in 2015 to
better discern those at low-risk from those at moderate- or
high-risk of ARF.21 This revision maintains major and minor
criteria, but these differ for low-risk and moderate-to highrisk populations. The changes to the diagnostic criteria were
an important update as ARF is rare in industrialized nations
and is no longer a reportable disease to the Centers for
Disease Control and Prevention (CDC).21,23,24 However, ARF
and rheumatic heart disease continue to be a major cause of
morbidity in low- and middle-income countries and in certain
populations, emphasizing the importance of timely diagnosis
and treatment of GAS tonsillitis in these groups to improve
population health.25e27

Diagnosis
Accurately diagnosing GAS pharyngitis is important to
reduce sequelae of untreated infection and to limit transmission. Since the majority of pediatric sore throats are
caused by viruses, accurate diagnosis of the etiology of
pharyngitis also prevents unnecessary antibiotic use. Clinical signs and symptoms, even when combined into prediction rules, are not reliable to diagnose GAS pharyngitis in
children.28 Testing by rapid antigen detection test (RADT) is
recommended by the Infectious Diseases Society of America
(IDSA) to definitely diagnose GAS pharyngitis.9 The sensitivity of RADTs, which is affected by specimen quality, is
generally reported to be 70%w90% when compared to blood
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agar plate culture.29e31 The IDSA and the American Heart
Association recommend back up culture for children with
negative RADTs, while the European guideline states throat
culture is not necessary after a negative RADT in children or
adults with acute sore throat.9,32,33 False positive RADT
results can occur in children recently treated for GAS
pharyngitis or when the test incubation period exceeds
manufacturer recommendations.34,35
Nucleic acid amplification tests (NAATs) offer greater
sensitivity than RADTs and provide a result in a shorter
turnaround time than culture. Some institutions have
replaced RADT-reflex culture algorithms with NAAT
alone.36 However, NAATs, RADTs, and throat culture do not
distinguish between GAS infection and colonization.
Appropriate patient selection for testing is necessary to
avoid misdiagnosis and unnecessary antibiotic exposure.
Testing for GAS pharyngitis is typically not indicated for
children <3 years old, or for patients of any age with
epidemiological and clinical features that suggest a viral
etiology of pharyngitis.9 Testing asymptomatic contacts of
patients with GAS pharyngitis is not routinely recommended unless the contacts are at increased risk of
developing sequelae from GAS infection, such as patients
with a history of ARF.9 Post-treatment testing is only recommended in special circumstances, such as patients at
high risk of ARF or patients with recurrence of symptoms
highly suggestive of GAS pharyngitis.

Table 1
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Treatment
Antibiotic therapy (Table 1) is indicated for patients with
signs and symptoms of pharyngitis and laboratory confirmation of GAS as the causative pathogen. GAS resistance to
penicillin has not been documented to date. Given its
narrow spectrum, low cost, and efficacy in preventing ARF,
penicillin is the drug of choice for treatment of GAS pharyngitis. Amoxicillin is a more palatable suspension than
penicillin V and is equally effective when used as a single
daily dose (50 mg/kg, max 1000 mg) for 10 days. Penicillin G
benzathine can be given as an intramuscular (IM) injection
in a single dose if medication adherence is uncertain;
however, the injection can be painful. For patients with
non-anaphylactic allergy to penicillin, a first-generation
cephalosporin, such as cephalexin, is appropriate therapy.
Clindamycin or a macrolide (e.g. azithromycin) can be used
for treatment in patients with anaphylactic, or Type 1 hypersensitivity, to penicillin.
For children who experience a recurrence of laboratory
confirmed GAS pharyngitis shortly after completion of antibiotic therapy, the same agent or an alternative agent
such as a narrow spectrum cephalosporin, amoxicillin-clavulanate, or a macrolide may be used. Laboratory confirmation of GAS isolate susceptibility should be considered when
non-beta lactam agents are used since high resistance rates
are reported in some geographic areas.37e40 Sulfonamides,

Antibiotic options for treatment of GAS pharyngitis.

Initial and recurrent episodes

Dose and duration

Considerations

PenicillinⅤ (oral)

If  27 kg: 250 mg per dose, two to three times
daily for 10 days
If > 27 kg: 500 mg per dose, two to three times
daily for 10 days
50 mg/kg once daily for 10 days; max dose
1000 mg
If < 27 kg: 600,000 U (375 mg) as single dose
If  27 kg: 1.2 million U (750 mg) intramuscular
as single dose
40 mg/(kg$d) divided twice daily for 10 days;
max dose 500 mg
20 mg/(kg$d) divided three times daily for 10
days; max dose 300 mg

Preferred therapy

Amoxicillin
Penicillin G benzathine (IM)

Cephalexin
Clindamycin

Azithromycin

Chronic pharyngeal carriage
Clindamycin
Penicillin V and rifampin

Amoxicillin/clavulanate
IM: Intramuscular injection.

Preferred therapy
Preferred therapy in situations of poor
medication adherence

12 mg/kg once on day 1 followed by 6 mg/kg
once daily on days
2w5; max dose 500 mg

Alternative therapy for children with
non-anaphylactic penicillin allergy
Alternative therapy for children with
anaphylactic penicillin allergy. Consider
testing to confirm susceptibility.
Alternative therapy for children with
anaphylactic penicillin allergy. Consider
testing to confirm susceptibility.

Dose and duration

Considerations

20w30 mg/(kg$d) divided three times daily for
10 days
Penicillin Ⅴ: 50 mg/(kg$d) divided four times
daily for 10 days; max 2000 mg/day rifampin:
20 mg/(kg$d) once daily for last 4 days of
treatment; max 600 mg/day
Amoxicillin：40 mg/(kg$d) divided three times
daily; max 2000 mg amoxicillin/day

Consider testing to confirm
susceptibility.
e

e
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tetracyclines, and fluoroquinolones should not be used for
treatment of GAS pharyngitis.
Repeated positive tests for GAS pharyngitis may represent chronic pharyngeal carriage of GAS in the setting of
viral pharyngitis or pharyngitis from another cause. Antibiotic therapy to eradicate GAS pharyngeal carriage is not
routinely indicated since carriers are at low, if any, risk of
developing complications and carriers are unlikely to
transmit infection.7,9 Eradication of GAS pharyngeal carriage may be indicated in the following special circumstances:(1) outbreaks of GAS pharyngitis in closed or semiclosed communities; (2) community outbreaks of invasive
GAS disease or community outbreaks of GAS complications
such as ARF; (3) family or personal history of ARF; (4)
multiple episodes of GAS pharyngitis within a household for
several weeks despite appropriate antibiotic therapy.9,12
Penicillin or amoxicillin may not be as effective in eradicating GAS pharyngeal carriage as other antibiotic agents
(Table 1).9 Reacquisition can occur after eradication is
achieved and pharyngeal carriage can persist for months to
years.41
Tonsillectomy solely for the purposes of decreasing the
frequency of GAS pharyngitis episodes is not routinely
recommended. If the frequency of pharyngitis episodes is
at least 7 episodes in one year, 5 episodes per year for 2
years, or 3 episodes per year for 2 years then tonsillectomy
should be considered. Tonsillectomy can also be considered
for recurrent pharyngitis if additional factors are present
such as history of peritonsillar abscess or multiple antibiotic
allergies.42
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Conclusions

14.

Tonsillitis is a common complaint prompting medical
attention and GAS as the cause of tonsillitis is a common
concern among patients and parents. Most cases of tonsillitis are viral in origin and patients who meet criteria for
testing should be determined by after obtaining a careful
history, reviewing seasonal epidemiology, and considering
physical exam findings. This approach aids in reducing unnecessary testing and subsequent antibiotic exposure and
reduces patient and societal healthcare costs.
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